Tag Archives: Principia Biopharma

H.C. Wainwright Believes Principia Biopharma (NASDAQ: PRNB) Won’t Stop Here

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Principia Biopharma (PRNB – Research Report), with a price target of $108.00. The company’s shares closed last Thursday at $87.24, close to its 52-week high

H.C. Wainwright Sticks to Its Buy Rating for Principia Biopharma (PRNB)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Principia Biopharma (PRNB – Research Report) today and set a price target of $77.00. The company’s shares closed last Wednesday at $60.04. According to TipRanks.com, Pantginis is a 5-star analyst

Principia Biopharma (PRNB) Received its Third Buy in a Row

After H.C. Wainwright and Wells Fargo gave Principia Biopharma (NASDAQ: PRNB) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Derek Archila reiterated a Buy rating on Principia Biopharma yesterday and set a

Stifel Nicolaus Sticks to Its Buy Rating for Principia Biopharma (PRNB)

In a report issued on March 29, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma (PRNB – Research Report), with a price target of $76.00. The company’s shares closed last Wednesday at $52.93. According to TipRanks.com,

Principia Biopharma (PRNB) Gets a Buy Rating from Wells Fargo

In a report released yesterday, Jim Birchenough from Wells Fargo maintained a Buy rating on Principia Biopharma (PRNB – Research Report). The company’s shares closed last Monday at $69.01, close to its 52-week high of $69.38. According to TipRanks.com, Birchenough

Principia Biopharma (PRNB) Receives a Buy from Stifel Nicolaus

In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Principia Biopharma (PRNB – Research Report). The company’s shares closed last Monday at $54.78. According to TipRanks.com, Archila is a 3-star analyst with an average